FOXO4-DRI, a synthetic peptide self-administered by people pursuing longevity, is built to make worn-out, non-dividing cells destroy themselves while sparing ordinary cells. In aged mice and laboratory-grown human cells it removed those cells, and kidney, activity, testosterone and blood-vessel measures improved. It has never been given to a person in a monitored study, raised lung blood pressures in rodents, and is sold only as a laboratory chemical of unverified content. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Cystatin C-based eGFR | Above 90 mL/min/1.73 m² | Kidney filtration, most consistently improved in animal work |
| Blood urea nitrogen (BUN) | 10–16 mg/dL | Primary filtration readout in the originating mouse studies |
| Creatinine | 0.7–1.1 mg/dL in men, 0.6–0.9 mg/dL in women | Second filtration marker, reduced in aged treated mice |
| Platelet count | 200–300 × 10⁹/L | Baseline makes any platelet fall interpretable |
| ALT and AST | Below 25 U/L each | AST was the liver-toxicity readout in the chemotherapy animal model |
| High-sensitivity CRP | Below 1.0 mg/L | Body-wide inflammatory signalling driven by senescent cells |
| Interleukin-6 (IL-6) | Below 1.8 pg/mL | Senescent-cell inflammatory signal most consistently lowered in animal tissue |
| Total testosterone (men) | 600–900 ng/dL | Recovered after clearance of senescent testosterone-producing cells in aged mice |
| p16INK4a expression in circulating T cells | No established target; track change from own baseline | Closest available proxy for total senescent-cell burden |
| GDF15 | No established target; track change from own baseline | Broad cellular-stress marker that rises with biological age |
Cadence: Baseline panel plus echocardiogram before any exposure; safety subset (complete blood count, liver enzymes, filtration markers) at 1 and 4 weeks after a cycle; full panel at 3 months, then every 6–12 months. Success is stability or improvement against own baseline.